STOCK TITAN
  1. Home
  2. News
  3. AFIB

Acutus Medical Inc - AFIB STOCK NEWS

Welcome to our dedicated news page for Acutus Medical (Ticker: AFIB), a resource for investors and traders seeking the latest updates and insights on Acutus Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acutus Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acutus Medical's position in the market.

News
Acutus Medical Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Acutus Medical, Inc. (AFIB) reported fourth-quarter and full-year results for 2023, showcasing significant revenue growth from Continuing Operations. The company's strategic realignment focused on optimizing financial position, with revenue from Continuing Operations increasing by 118% to $2.4 million in the fourth quarter and by 136% to $7.2 million for the full year. Gross margin improved to negative 44%, operating expenses decreased to $17.5 million, and net loss on continuing operations was $11.9 million. Cash reserves stood at $29.4 million. However, a loss of $69.7 million from Discontinued Operations was recorded, leading to the decision to no longer provide financial guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
earnings
-
News
Acutus Medical to Cancel Third Quarter 2023 Conference Call
Rhea-AI Summary
Acutus Medical, Inc. (Nasdaq: AFIB) Cancels Q3 Results Conference Call and Webcast After Strategic Realignment and Corporate Restructuring
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Acutus Medical Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Acutus Medical, Inc. (Nasdaq: AFIB) reported third quarter 2023 revenue of $5.2 million, a 44% year-over-year growth, driven by strong distribution revenue from sales of left-heart access products to Medtronic. The company also achieved significant reductions in operating expenses and cash burn, and announced a strategic realignment of resources and corporate restructuring to optimize financial position and maximize free cash flow.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50.85%
Tags
earnings
News
Acutus Medical Announces Strategic Realignment of Resources and Corporate Restructuring
Rhea-AI Summary
Acutus Medical, Inc. (Nasdaq: AFIB) announced a strategic realignment of resources and corporate restructuring, shifting focus to manufacturing left-heart access products for Medtronic to maximize potential earnouts and cash flow. The company will discontinue its EP mapping and ablation business, reduce its workforce by approximately 65%, and expects to generate positive cash flow over the next several years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50.85%
Tags
none
-
News
Acutus Medical to Announce Third Quarter 2023 Financial Results
Rhea-AI Summary
Acutus Medical, Inc. will release its third quarter 2023 financial results on November 13, 2023. A conference call and webcast will be held to discuss the results and recent highlights. Participants can access the live call via telephone or the Acutus investor relations website. A replay of the webinar will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.02%
Tags
earnings
-
News
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Acutus Medical, Inc. granted equity awards to 5 individuals hired in October 2023. The employees received a total of 28,500 restricted stock units (RSUs), with vesting occurring yearly on each anniversary of the grant date. The RSUs will be fully vested on the fourth anniversary of the grant date, contingent on continued employment with Acutus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.02%
Tags
none
News
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Acutus Medical grants equity awards to 3 new employees, totaling 28,000 RSUs, as a material inducement to employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
none
-
News
Acutus Medical Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Acutus Medical, Inc. (Nasdaq: AFIB) reported strong second-quarter results, with revenue growing 30% year-over-year to $5.3 million. The company achieved record procedure volumes, received FDA clearance for AcQMap 9, and significantly improved non-GAAP gross margin and cash burn. Despite a non-GAAP net loss of $17.6 million, Acutus expects full-year 2023 revenue to be in the range of $20.0-$22.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.73%
Tags
earnings
-
News
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Acutus Medical, Inc. (Nasdaq: AFIB) grants equity awards to 3 new employees as inducement to employment, totaling 38,500 restricted stock units (RSUs) under the 2022 Inducement Equity Incentive Plan, with vesting scheduled annually over 4 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
none
News
Acutus Medical to Present at the 43rd Annual Canaccord Growth Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.21%
Tags
conferences
Stock AFIB logo
Acutus Medical Inc

Nasdaq:AFIB

AFIB Rankings

N/A Ranked by Market Cap
#4022 Ranked by Stock Gains
N/A Ranked by Dividends

AFIB Stock Data

4.88M
23.42M
3.61%
23.55%
2.84%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Carlsbad

About AFIB

world class talent with the mission to reshape ep acutus medical has attracted some of the most respected pioneers and leaders in electrophysiology and cardiac device manufacturing to join our organization and our worldwide network of collaborative partners. the common bond that brings us together is our passion and collective capability to revolutionize a field that has not seen major technological advances in decades. our mission of continual innovation is focused on providing electrophysiologists with the highest quality suite of tools, coupled with outstanding clinical and technical support, to better understand and effectively treat complex arrhythmias. electrophysiology is a high growth market with a clear need for a leap-frog technology to address the unmet need for a scientific, medical evidence-based approach to treating atrial fibrillation, ventricular tachycardia and the other complex arrhythmia's. acutus medical is a full-portfolio solution provider for treating these patie